Meprobamate

甲丙氨酯

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameMeprobamate
Drug Alias Name安宁meprobamatomeprobamatum眠尔通氨甲丙二酯 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGamma-aminobutyric acid A receptor agonists
TargetsGamma-aminobutyric acid A receptor
Therapy Area/IndicationsAnxiety DisordersAnxietySleep Initiation and Maintenance Disorders +[5] 
Global Approved IndicationsAnxiety DisordersAnxietySleep Initiation and Maintenance Disorders +[5] 
Approved Indications in ChinaAnxietySleep Initiation and Maintenance DisordersEpilepsy +[4] 
Original Approved Country/TerritoryUnited States
Original Approved Date1955/07/26
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesGrand Pharmaceutical （China） Co Ltd
Inactive CompaniesWyeth-Ayerst
Active IndicationsAnxietySleep Initiation and Maintenance DisordersEpilepsy +[4] 
Inactive IndicationsAnxiety Disorders

Other Information

ATC CodeN05BC01
Related LinksWikipediaDrugBankKEGG